BBOT
BridgeBio Oncology Therapeutics Inc.
Biotechnology
Market Cap$185M
5Y Perf.-26.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BBOT vs KYMR
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.91B
5Y Perf.+101.6%
BBOT vs KYMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BBOT | KYMR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $185M | $6.91B |
| Revenue (TTM) | $0.00 | $51M |
| Net Income (TTM) | $-134M | $-315M |
| Gross Margin | — | 33.2% |
| Operating Margin | — | -7.0% |
| Total Debt | $3M | $82M |
| Cash & Equiv. | $374M | $357M |
BBOT vs KYMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BBOT
KYMR
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 73.9 | -26.1% |
| Kymera Therapeutics… (KYMR) | 100 | 201.6 | +101.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BBOT vs KYMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYMR leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. BridgeBio Oncology Therapeutics Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BBOT
BridgeBio Oncology Therapeutics Inc.
The Income Pick
BBOT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.96
- Lower volatility, beta 0.96, Low D/E 0.7%, current ratio 12.14x
- Beta 0.96, current ratio 12.14x
Best for: income & stability and sleep-well-at-night
KYMR
Kymera Therapeutics, Inc.
The Growth Play
KYMR carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -16.7%, EPS growth -23.8%, 3Y rev CAGR -5.8%
- 154.4% 10Y total return vs BBOT's -22.9%
- -16.7% revenue growth vs BBOT's -80.5%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KYMR | -16.7% revenue growth vs BBOT's -80.5% |
| Stability / Safety | BBOT | Beta 0.96 vs KYMR's 1.15, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYMR | +190.7% vs BBOT's -27.6% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs BBOT's -41.9%, ROIC -24.9% vs -96.3% |
BBOT vs KYMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGBBOT
BBOTBridgeBio Oncology Th…
0leads
KYMRKymera Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs BBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KYMR and BBOT operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $51M |
| EBITDAEarnings before interest/tax | -$166M | -$352M |
| Net IncomeAfter-tax profit | -$134M | -$315M |
| Free Cash FlowCash after capex | -$95M | -$244M |
| Gross MarginGross profit ÷ Revenue | — | +33.2% |
| Operating MarginEBIT ÷ Revenue | — | -7.0% |
| Net MarginNet income ÷ Revenue | — | -6.1% |
| FCF MarginFCF ÷ Revenue | — | -4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -21.2% | +13.4% |
KYMR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BBOT and KYMR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $185M | $6.9B |
| Enterprise ValueMkt cap + debt − cash | -$186M | $6.6B |
| Trailing P/EPrice ÷ TTM EPS | -1.83x | -22.93x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 176.26x |
| Price / BookPrice ÷ Book value/share | 0.60x | 4.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BBOT and KYMR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KYMR leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-66 for BBOT. BBOT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x.
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -65.5% | -25.0% |
| ROA (TTM)Return on assets | -41.9% | -22.3% |
| ROICReturn on invested capital | -96.3% | -24.9% |
| ROCEReturn on capital employed | -48.0% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.05x |
| Net DebtTotal debt minus cash | -$371M | -$275M |
| Cash & Equiv.Liquid assets | $374M | $357M |
| Total DebtShort + long-term debt | $3M | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x |
KYMR leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $19,212 today (with dividends reinvested), compared to $7,713 for BBOT. Over the past 12 months, KYMR leads with a +190.7% total return vs BBOT's -27.6%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs BBOT's -8.3% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -36.0% | +16.3% |
| 1-Year ReturnPast 12 months | -27.6% | +190.7% |
| 3-Year ReturnCumulative with dividends | -22.9% | +205.1% |
| 5-Year ReturnCumulative with dividends | -22.9% | +92.1% |
| 10-Year ReturnCumulative with dividends | -22.9% | +154.4% |
| CAGR (3Y)Annualised 3-year return | -8.3% | +45.0% |
KYMR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BBOT and KYMR each lead in 1 of 2 comparable metrics.
Risk & Volatility
BBOT is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than KYMR's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 82.2% from its 52-week high vs BBOT's 52.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.03x |
| 52-Week HighHighest price in past year | $14.87 | $103.00 |
| 52-Week LowLowest price in past year | $7.63 | $28.06 |
| % of 52W HighCurrent price vs 52-week peak | +52.9% | +82.2% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 306K | 602K |
Evenly matched — BBOT and KYMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BBOT as "Buy" and KYMR as "Buy". Consensus price targets imply 175.7% upside for BBOT (target: $22) vs 39.5% for KYMR (target: $118).
| Metric | BBOTBridgeBio Oncolog… | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.67 | $118.06 |
| # AnalystsCovering analysts | 3 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 3 of 6 categories
Loading custom metrics...
BBOT vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BBOT or KYMR a better buy right now?
Analysts rate BridgeBio Oncology Therapeutics Inc.
(BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BBOT or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +92. 1%, compared to -22. 9% for BridgeBio Oncology Therapeutics Inc. (BBOT). Over 10 years, the gap is even starker: KYMR returned +158. 8% versus BBOT's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BBOT or KYMR?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc.
(BBOT) is the lower-risk stock at 0. 96β versus Kymera Therapeutics, Inc. 's 1. 03β — meaning KYMR is approximately 7% more volatile than BBOT relative to the S&P 500. On balance sheet safety, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a lower debt/equity ratio of 1% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BBOT or KYMR?
On earnings-per-share growth, the picture is similar: Kymera Therapeutics, Inc.
grew EPS -23. 8% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BBOT or KYMR?
BridgeBio Oncology Therapeutics Inc.
(BBOT) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BBOT leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BBOT or KYMR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BBOT or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +158. 8% 10Y return). Both have compounded well over 10 years (KYMR: +158. 8%, BBOT: -24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BBOT and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.